An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Alkermes Pathways Research Awards Is Now Accepting Applications!
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
The Alkermes Pathways Research Awards are open for applications! The program provides opportunities for individual grants of up to $100,000 per research project for early-career investigators focused on research relating to schizophrenia or bipolar disorder.
Positive
Individual grants of up to $100,000 per research project for early-career investigators
Negative
None.
NORTHAMPTON, MA / ACCESSWIRE / September 19, 2023 / The Alkermes Pathways Research Awards are open for applications! This program is open to all early-career investigators studying bipolar disorder or schizophrenia.
With millions of people impacted by neurological disorders, more research is urgently needed to advance science in this area. The Alkermes Pathways Research Awards® program is designed to support the next generation of researchers who are working on the front lines to advance understanding of diseases in the field of neuroscience. This year's application cycle is now open.
The Alkermes Pathways Research Awards program provides opportunities for individual grants of up to $100,000 per research project for early-career investigators focused on research relating to schizophrenia or bipolar disorder. Watch this video to learn more and visit the Alkermes website to apply. https://www.alkermes.com/research-and-development/pathways
alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (cns) diseases. the company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. headquartered in dublin, ireland, alkermes plc has an r&d center in waltham, massachusetts; a research and manufacturing facility in athlone, ireland; and a manufacturing facility in wilmington, ohio. for more information, please visit alkermes’ website at www.alkermes.com.
